YC W25
Delineate
Agents for Accelerated Clinical Trial Design
About
Delineate is building AI agents to design better clinical trials faster. This is a $10B dollar market, where saving even 1 day along the process is equal to $1-5M in revenue potential. We process existing clinical trial research into specialized datasets saving scientists months of effort. Delineate is working with two of the largest pharmaceutical companies. With one of our customers, we are helping them get to the next phase of trials faster by creating the largest dataset on a drug class ever constructed.
Founders
- Emily Nieves
- Jawad Iqbal
Family Office Investors
Altss tracks family office allocations to YC-backed companies. Request access to see which family offices have invested in Delineate.
See family office activityIndustry & Focus
B2BEngineering, Product and DesignSaaSBiotechAI